ODAC to discuss Yondelis

FDA's Oncologic Drugs Advisory Committee will meet on July 15 to discuss an NDA from Johnson & Johnson (NYSE:JNJ) for Yondelis trabectedin in combination with Doxil doxorubicin to treat relapsed ovarian cancer. J&J has rights to Yondelis outside of Europe and Japan from Zeltia Group (Madrid:ZEL) subsidiary PharmaMar S.A., which markets the cytotoxic alkaloid that binds the minor groove of DNA for soft tissue sarcoma in the EU. ...